Abstract
No AccessJournal of UrologyCLINICAL UROLOGY: Case Reports1 Aug 2001RESPONSE OF HORMONE REFRACTORY PROSTATE CANCER TO LYCOPENE BRIAN R. MATLAGA, M. CRAIG HALL, DIANA STINDT, and FRANK M. TORTI BRIAN R. MATLAGABRIAN R. MATLAGA More articles by this author , M. CRAIG HALLM. CRAIG HALL Financial interest and/or other relationship with Helios Health. Com, Praecis Pharmaceutical, Inc. and Schering. More articles by this author , DIANA STINDTDIANA STINDT More articles by this author , and FRANK M. TORTIFRANK M. TORTI More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)66000-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "RESPONSE OF HORMONE REFRACTORY PROSTATE CANCER TO LYCOPENE." The Journal of Urology, 166(2), p. 613 References 1 : Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst1999; 91: 317. Google Scholar 2 : Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res1999; 59: 1225. Medline, Google Scholar 3 : Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol2000; 163: 1451. Link, Google Scholar From the Department of Urology and Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySchwenke C, Ubrig B, Thürmann P, Eggersmann C and Roth S (2018) Lycopene for Advanced Hormone Refractory Prostate Cancer: A Prospective, Open Phase II Pilot StudyJournal of Urology, VOL. 181, NO. 3, (1098-1103), Online publication date: 1-Mar-2009. Volume 166Issue 2August 2001Page: 613 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordsprostateprostatic neoplasmsabnormalitiesMetricsAuthor Information BRIAN R. MATLAGA More articles by this author M. CRAIG HALL Financial interest and/or other relationship with Helios Health. Com, Praecis Pharmaceutical, Inc. and Schering. More articles by this author DIANA STINDT More articles by this author FRANK M. TORTI More articles by this author Expand All Advertisement PDF downloadLoading ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
